It's a weird way to play the market, but those stocks do seem to find a way to get back over $1.......and then often fall back under that mark.
OT: Stock and Investment Talk
- Thread starter RU-05
- Start date
We created a custom basket for my daughter (6th grade) at the start of 2023. She selected the following:
VTI - 30%
RBLX - 10%
AAPL - 10%
GOOGL - 10%
DIS - 10%
Chipotle - 10%
SBUX - 10%
McDonald's - 10%
At the start of the last trading day of the year, she is up 31% and easily beating the S&P 500!!! :)
What's the goal of your son's account? Buying what you know/like is always a good start.
Up another 15% today. Up 100% from it's lows earlier this week.
Still down about 60% on the 3 month chart. Down 99.9% on the one year. Add some more 9's to that on the 3 year.
I'm relatively new to this stock game but it seems to be a pretty bizarre case.
They are now making deliveries, with a pretty big contract to fullfill, so I'm hoping there is a lot more to this upward move.
Last edited:
Lol, I only mentioned the NASDAQ compliance for context. I actually believe in the company and the products in their pipeline.
Not familiar with Ocugen, but will check it out. I have a small biotech play right now with Cellectar Biosciences (CLRB). They are announcing topline data at the upcoming JP Morgan conference, second week in Jan. Check out their recent press releases. All public signs point to positive data, but you never know. This one will likely 10x or go bankrupt soon. LOL!
Seems super heavy into Covid and flu vaccine's. Maybe this is a chance to buy low on those plays(tons of Covid going around now) but Covid vax has been a major drag on the likes of Pfizer.
That's a wise POV on biotech. I've been invested in PRHSX for 15+ years (traditional HC and biotech). Making a play with XBI in 2024 would also be a good idea. It's the most interest rate sensitive sub-sector of the market and we are starting a rate cutting cycle.
I also still have a sizable position in CURE. I believe HC will have a solid 2024.
I'd say maybe buy one share of MULN, but that would be more then 10% of the portfolio. Don't think anyone should be that heavily weighted towards a total POS.
MULN stock is now $15'ish? That must have been one hell of a reserved stock split! More elbow room for puts now. :)
I think he’d learn best from buying what he knows. Maybe some NVIDIA if he’s into video games
The future for Ocugen is Neocart (for knee cartilage) and Ocu400 treatment for retinal diseases. They have had successful Phase I and II trials for both. This year (2024) will be the early stages of a breakout for them, as Phase III trials progress. Manufacturing planned for 2025 and revenue ramping up into the billions starting in 2026.
Their stock has some traction now (steady climb for the last 2 weeks) because investors can foresee the breakout is coming (though still somewhat premature), possibly by the end of 2024 if approvals occur.
The COVID stuff is mostly behind them (they had a partnership with Covaxin) but they do have a promising nasal spray in development.
100-1.
I actually liked it better when I owned thousands of shares. Much more fun that way.
Recent statement by Ocugen CEO who worked for Pfizer for 15 years and led the Prevnar team):
OCU400 Phase 3 - exciting times ahead in early 2024!!
Company received alignment from FDA on key aspects of the Phase 3 clinical trial design to assess the safety and efficacy of OCU400 in patients with RHO and other gene mutations associated with Retinitis Pigmentosa (RP).
“This news brings us even closer to fulfilling our mission to bring our first-in-class, gene-agnostic therapies to market and provide access to patients globally,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “We look forward to beginning the Phase 3 clinical trial, which we plan to initiate in early 2024.”
OCU400 Phase 3 - exciting times ahead in early 2024!!
Company received alignment from FDA on key aspects of the Phase 3 clinical trial design to assess the safety and efficacy of OCU400 in patients with RHO and other gene mutations associated with Retinitis Pigmentosa (RP).
“This news brings us even closer to fulfilling our mission to bring our first-in-class, gene-agnostic therapies to market and provide access to patients globally,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “We look forward to beginning the Phase 3 clinical trial, which we plan to initiate in early 2024.”
Frick. I am such a sucker for expected growth. (E-trade has them at 166m in 2026, which would be more then current market cap).
And I bought some.
Thanks for the insight — did not know the E-trade projection. Good luck to both of us.
Were you pumping this stock in 2020?
I think I remember someone being big on it. Think I was in it for a bit. Might have made some money on it.
But the E-trade projection does align to what you are saying in terms of when they start bringing in rev's. That is as far as they go out though.
May have to buy some as well. This one looks like a winner.....if they get the needed FDA approvals.
EDIT: Started reading about OCU400, looks like a competitor to Luxturna from Spark/Roche. That's one of the first gene therapies ever approved, but has limitations that OCU400 looks to mitigate. Very interesting. Much more to read.
Current corporate deck:
Last edited:
Not sure if I mentioned it in 2020 but it’s possible, since I did own some back then.
Yes, if you’re looking to hold a pre-revenue stock with a lot of upside that is moving along the trial phases nicely, this is a good bet imo (not giving advice, just my opinion).
It has a good chance to get above $1.00 by the end of April (a 72% gain from where it is today) but if not, you can expect a reverse split, just so you’re aware. I’m not concerned though, because in my mind that would just be a formality to be in NASDAQ compliance on their way to major gains as their trials conclude and FDA approval is granted.
Do you know the last time they raised? They had about $55m at the end of Q3 (Sept 30) and has a quarterly burn rate of $14m'ish. They need to raise again very soon (if they didn't already).
Gotta listen to The Man in 2024! 2023 is in the books and it was an amazing year. Looking forward to updating my performance spreadsheet over the weekend.
Weekly streak of positive returns still rolling for all 3 indexes:
S&P 500 falls slightly Friday, but rides 9-week win streak to end 2023 with 24% gain: Live updates
Stocks fell slightly on Friday, but the S&P 500 closed out 2023 with a surprising gain of 24%.
Last edited:
Excellent 2024 outlook and ideas from Morningstar (stocks and bonds):
www.morningstar.com
Chart #1:
Chart #2:
Our Best Investment Ideas for 2024
We see opportunities in both stocks and bonds in the year ahead.
Chart #1:
Chart #2:
I believe their last offering was in May (30 million shares, raised $16.5 million).
2023 results:
VOO (S&P 500 plus dividends) was up 26.3%
Our entire portfolio was up 34.2% (BOOM!)
My personal/fun account was up 123.7% (KABOOM!)
What a great year. Onwards to 2024! :)
VOO (S&P 500 plus dividends) was up 26.3%
Our entire portfolio was up 34.2% (BOOM!)
My personal/fun account was up 123.7% (KABOOM!)
What a great year. Onwards to 2024! :)
Do you use fidelity for managing all your accounts? Does it have these stats?
good luck to everyone in the new year
God Bless, hope you all do well in life and in your accounts
God Bless, hope you all do well in life and in your accounts
Unfortunately, no. We have 9 accounts across Fidelity, T Rowe, E-Trade, Ally, Voya, and TIAA CREF (long story). So, I need to get the performance from each account and put the data into a spreadsheet to weigh the accounts by size. The math is simple, but it takes a bit of time to log into everything.
We have 3 accounts in Fidelity.....personal/fun, rollover IRA, and Fidelity crypto. I don't think they have a summary performance calculation for these accounts. All such info is separate.
The only way I know to automatically track different accounts across an entire portfolio is Morningstar's portfolio manager. This is a premium service. I use it for 6 accounts to track for quick reference, but it is a little wonky and probably more time consuming than doing it manually. Morningstar's X-Ray service is awesome. It shows you a summary stock list for an account or portfolio across all holdings, even ETFs and mutual funds.
T2K any opinion on TEVA? Someone mentioned it to me recently but I tend to steer clear of this sector because I have had little success.
TEVA is undervalued and probably a sleeping giant. So why is this happening? TEVA took on a crazy amount of debt buying Allergan and a few other meh companies. They generate a ton of free cash flow, but it is sucked up paying off debt. They instead need to use this money to innovate and make new strategic acquisitions.
I know a lot of folks at TEVA, they even tried to recruit me a few years ago. I think they will be stuck in the mud for a few more years, but when the debt is mitigated and they turn the corner, look out! They have a few great branded products and a growing biosimilar pipeline. I bet the stock will rip when this happens. An investor may need to wait for 3-5 years. However, the stock market is forward looking, so perhaps TEVA starts to drift higher sooner?
Good summary chart:
You could try Personal Capital. I use it to track all of my accounts from banking to investments and credit cards etc. pretty good platform
20%+ return years are always a blast! As for retirement, we are not close yet, but can see it in the distance horizon. LOL! So many articles say you need whatever your target is ($X) on the day you retire. However, you don't need all that money on day one. Much of it is going to stay invested for a long, long time. Sure, the days of TQQQ trades will be over, but basic indexes should have significant allocations.
So, do you need a set # or just enough to live on for 4-5 years without tapping into the remaining investments? Advice on retirement seems to be evolving.
So what do we suppose is the inflection point in terms of debt?TEVA is undervalued and probably a sleeping giant. So why is this happening? TEVA took on a crazy amount of debt buying Allergan and a few other meh companies. They generate a ton of free cash flow, but it is sucked up paying off debt. They instead need to use this money to innovate and make new strategic acquisitions.
I know a lot of folks at TEVA, they even tried to recruit me a few years ago. I think they will be stuck in the mud for a few more years, but when the debt is mitigated and they turn the corner, look out! They have a few great branded products and a growing biosimilar pipeline. I bet the stock will rip when this happens. An investor may need to wait for 3-5 years. However, the stock market is forward looking, so perhaps TEVA starts to drift higher sooner?
Good summary chart:
And do we think they can get back to growth. Flat earnings and Rev's.
Building a base though. And cheap.
Its debt is now under $20B and probably needs to get back to $12B'ish. Or at least give the street confidence they are on a glide path to this level. So that's the tricky question. I think it will take another 3-4 years to get to $12B, but it is likely the market will reward them well before it actually happens.
Their current products are solid, good pipeline, and quality commercial team. They just made a monumentally stupid decision to buy Allergan and take on all that debt. TEVA is now on my watchlist. If it drifts back down to $9'ish, I may buy. I don't think it will breakdown below the recent trading range, so it should have a strong floor.
This is not a short term trade. It's a 5+ year commitment, but the stock may get back to ATHs by the end of the decade.
Latest posts
-
Olympic Sports Rutgers Softball Returns with Youth Movement This Season
- Latest: MarkInCapeMay
-
-
